drugset / Trial / NCT06123663

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

NCT06123663 ↗

Phase 1 Completed 60 enrolled CanSino Biologics Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of Tetanus Vaccine, Adsorbed (TTVA) or control vaccine.

Timeline

Start
2023-12-20
Primary completion
2024-01-23
Completion
2024-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Tetanus Vaccine, Adsorbed Vaccine 0.5 ml Intramuscular
Comparator Tetanus Vaccine, Adsorbed Vaccine 0.5 ml Intramuscular

Indications